Database : MEDLINE
Search on : Burkholderia and Infections [Words]
References found : 3730 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 373 go to page                         

  1 / 3730 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29509962
[Au] Autor:Marom A; Miron D; Wolach B; Gavrieli R; Rottem M
[Ad] Address:Department of Pediatrics A, Emek Medical Center, Afula, and Rappaport faculty of medicine, Technion- Israel Institute of Technology, HaifaIsrael.
[Ti] Title:Burkholderia Gladioli- Associated Facial Pustulosis as a First Sign of Chronic Granulomatous Disease in a Child.- Case Report and Review.
[So] Source:Pediatr Allergy Immunol;, 2018 Mar 06.
[Is] ISSN:1399-3038
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Burkholderia gladioli is a rod-shaped gram-negative aerobic bacteria associated mostly with plant pathology, it's role as a human pathogen is rare. Infections due to B. Gladioli have been reported in individuals who were immune suppressed. We present the case of a 13-month-old child for whom a diagnosis of chronic granulomatous disease (CGD) was made following skin and lymph node infection with Burkholderia gladioli. This is one of the few reported cases in children and the second in which this bacterial infection was the sole manifestation of CGD. This article is protected by copyright. All rights reserved.
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher
[do] DOI:10.1111/pai.12884

  2 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29498745
[Au] Autor:Teri A; Sottotetti S; Biffi A; Girelli D; D'Accico M; Arghittu M; Colombo C; Corti F; Pizzamiglio G; Cariani L
[Ad] Address:Cystic Fibrosis Microbiology Laboratory, IRCCS Ca' Granda, Milan, Italy.
[Ti] Title:Molecular typing of Burkholderia cepacia complex isolated from patients attending an Italian Cystic Fibrosis Centre.
[So] Source:New Microbiol;41(1), 2018 Mar 02.
[Is] ISSN:1121-7138
[Cp] Country of publication:Italy
[La] Language:eng
[Ab] Abstract:Bacteria from the Burkholderia cepacia complex (Bcc) are capable of causing severe infections in patients with cystic fibrosis (CF). Bcc infection is often extremely difficult to treat due to its intrinsic resistance to multiple antibiotics. In addition, it seems to speed up the decline of lung function and is considered a contraindication for lung transplantation in CF. This study investigates the species of the Bcc strains recovered from chronically infected CF subjects by means of: isolation, identification methods and complete recA nucleotide sequences of 151 samples. Molecular typing showed that B. cenocepacia III is the dominant strain found in the group of subjects being treated at the Milan CF Centre (Italy) and that the infection is chronically maintained by the same species. Defining species by means of molecular analysis yields important information for the clinician in order to establish the most appropriate therapy and implement correct measures for prevention of transmission among CF subjects.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:Publisher

  3 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29208262
[Au] Autor:Chou DW; Lin YW
[Ad] Address:Department of Critical Care Medicine, Tainan Municipal Hospital, Tainan, Taiwan. Electronic address: choudw@gmail.com.
[Ti] Title:Splenic Infarction and Rupture Due to Melioidosis.
[So] Source:Am J Med Sci;354(6):633-634, 2017 12.
[Is] ISSN:1538-2990
[Cp] Country of publication:United States
[La] Language:eng
[Mh] MeSH terms primary: Melioidosis/diagnostic imaging
Rupture, Spontaneous/diagnostic imaging
Splenic Infarction/diagnostic imaging
Splenic Rupture/diagnostic imaging
[Mh] MeSH terms secundary: Diabetes Complications/diagnostic imaging
Female
Humans
Melioidosis/complications
Middle Aged
Rupture, Spontaneous/etiology
Splenic Infarction/etiology
Splenic Rupture/etiology
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171207
[St] Status:MEDLINE

  4 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29461800
[Au] Autor:Daly SM; Sturge CR; Marshall-Batty KR; Felder-Scott CF; Jain R; Geller BL; Greenberg DE
[Ad] Address:Department of Internal Medicine, UT Southwestern , 5323 Harry Hines Blvd, Dallas, Texas 75390, United States.
[Ti] Title:Antisense Inhibitors Retain Activity in Pulmonary Models of Burkholderia Infection.
[So] Source:ACS Infect Dis;, 2018 Mar 01.
[Is] ISSN:2373-8227
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The Burkholderia cepacia complex is a group of Gram-negative bacteria that are opportunistic pathogens in immunocompromised individuals, such as those with cystic fibrosis (CF) or chronic granulomatous disease (CGD). Burkholderia are intrinsically resistant to many antibiotics and the lack of antibiotic development necessitates novel therapeutics. Peptide-conjugated phosphorodiamidate morpholino oligomers are antisense molecules that inhibit bacterial mRNA translation. Targeting of PPMOs to the gene acpP, which is essential for membrane synthesis, lead to defects in the membrane and ultimately bactericidal activity. Exploration of additional PPMO sequences identified the ATG and Shine-Dalgarno sites as the most efficacious for targeting acpP. The CF lung is a complex microenvironment, but PPMO inhibition was still efficacious in an artificial model of CF sputum. PPMOs had low toxicity in human CF cells at doses that were antibacterial. PPMOs also reduced the bacterial burden in the lungs of immunocompromised CyBB mice, a model of CGD. Finally, the use of multiple PPMOs was efficacious in inhibiting the growth of both Burkholderia and Pseudomonas in an in vitro model of coinfection. Due to the intrinsic resistance of Burkholderia to traditional antibiotics, PPMOs represent a novel and viable approach to the treatment of Burkholderia infections.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:Publisher
[do] DOI:10.1021/acsinfecdis.7b00235

  5 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29384621
[Au] Autor:Jasim R; Schneider EK; Han M; Azad MAK; Hussein M; Nowell C; Baker MA; Wang J; Li J; Velkov T
[Ti] Title:A Fresh Shine onCystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles.
[So] Source:J Biomed Nanotechnol;13(4):447-57, 2017 Apr.
[Is] ISSN:1550-7033
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:This in vitro study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with 2 nm silver nanoparticles (NPs) against Gram-negative pathogens commonly isolated from the cystic fibrosis (CF) lung. The in vitro synergistic activity of polymyxin B with silver NPs was assessed using the checkerboard assay against polymyxinsusceptible and polymyxin-resistant Pseudomonas aeruginosa isolates from the lungs of CF patients. The combination was also examined against the Gram-negative species Haemophilus influenzae, Burkholderia cepacia, Burkholderia pseudomallei, Stenotrophomonas maltophilia, Klebsiella pneumoniae and Acinetobacter baumannii that are less common in the CF lung. The killing kinetics of the polymyxin B-silver NPs combinations was assessed against P. aeruginosa by static time-kill assays over 24 h. Polymyxin B and silver NPs alone were not active against polymyxin-resistant (MIC ≥4 mg/L) P. aeruginosa. Whereas, the combination of a clinically-relevant concentration of polymyxin B (2 mg/L) with silver NPs (4 mg/L) successfully inhibited the growth of polymyxin-resistant P. aeruginosa isolates from CF patients as demonstrated by ≥2 log10 decrease in bacterial count (CFU/mL) after 24 h. Treatment of P. aeruginosa cells with the combination induced cytosolic GFP release and an increase of cellular reactive oxygen species. In the nitrocefin assay, the combination displayed a membrane permeabilizing activity superior to each of the drugs alone. The combination of polymyxin B and silver NPs displays excellent synergistic activity against highly polymyxin-resistant P. aeruginosa and is potentially of considerable clinical utility for the treatment of problematic CF lung infections.
[Mh] MeSH terms primary: Bacterial Physiological Phenomena/drug effects
Cystic Fibrosis/drug therapy
Cystic Fibrosis/microbiology
Metal Nanoparticles/administration & dosage
Pneumonia, Bacterial/diagnostic imaging
Polymyxin B/administration & dosage
Silver/administration & dosage
[Mh] MeSH terms secundary: Administration, Inhalation
Anti-Infective Agents/administration & dosage
Anti-Infective Agents/chemistry
Cell Survival/drug effects
Cystic Fibrosis/pathology
Diffusion
Dose-Response Relationship, Drug
Drug Combinations
Drug Synergism
Humans
Metal Nanoparticles/chemistry
Pneumonia, Bacterial/microbiology
Polymyxin B/chemistry
Respiratory Therapy/methods
Silver/chemistry
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Anti-Infective Agents); 0 (Drug Combinations); 1404-26-8 (Polymyxin B); 3M4G523W1G (Silver)
[Em] Entry month:1802
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[Js] Journal subset:IM
[Da] Date of entry for processing:180201
[St] Status:MEDLINE

  6 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29338445
[Au] Autor:Antoniu SA
[Ad] Address:a Department of Medicine II-Nursing/Palliative Care , University of Medicine and Pharmacy Grigore T Popa Iasi , Iasi , Romania.
[Ti] Title:Investigational inhaled therapies for non-CF bronchiectasis.
[So] Source:Expert Opin Investig Drugs;27(2):139-146, 2018 Feb.
[Is] ISSN:1744-7658
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Bronchiectasis not related to cystic fibrosis (non-CF bronchiectasis) are associated with a high unmet therapeutic need due to the lack of specifically authorized medications, especially via the inhalation route. In non-CF bronchiectasis chronic infection with Pseudomonas aeruginosa is common and favored by the persistent local inflammation and viscid sputum production. Therefore inhaled antibiotics, mucolytics or anti-inflammatory agents could represent appropriate therapeutic interventions in this setting Areas covered: This review herein discusses the inhaled therapies currently under investigation for non-CF bronchiectasis and their potential therapeutic positioning in exacerbation versus stable state. Expert opinion: Inhaled antipseudomonal antibiotics are of promising efficacy, but further efforts should also be made to detect bactericidal approaches against Burkholderia cepacia complex, and to interfere chronic inflammation topically.
[Mh] MeSH terms primary: Bronchiectasis/drug therapy
Drug Design
Drugs, Investigational/therapeutic use
[Mh] MeSH terms secundary: Administration, Inhalation
Animals
Anti-Bacterial Agents/administration & dosage
Anti-Bacterial Agents/therapeutic use
Anti-Inflammatory Agents/administration & dosage
Anti-Inflammatory Agents/therapeutic use
Bronchiectasis/etiology
Bronchiectasis/microbiology
Chronic Disease
Drugs, Investigational/administration & dosage
Drugs, Investigational/pharmacology
Expectorants/administration & dosage
Expectorants/therapeutic use
Humans
Pseudomonas Infections/drug therapy
Pseudomonas aeruginosa
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents); 0 (Drugs, Investigational); 0 (Expectorants)
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[Js] Journal subset:IM
[Da] Date of entry for processing:180118
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1427728

  7 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29429458
[Au] Autor:Peng F; Zhong LL; Lin XJ; Chen M; Zhou M
[Ad] Address:Department of Pediatrics, Hunan Provincial People's Hospital, Changsha 410000, China. 570047414@qq.com.
[Ti] Title:[Burkholderia cepacia infection in children: a clinical analysis of 16 cases].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;20(2):112-115, 2018 Feb.
[Is] ISSN:1008-8830
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:OBJECTIVE: To investigate the distribution characteristics and clinical features of Burkholderia cepacia infection in children. METHODS: A retrospective analysis was performed for the clinical data of 16 children with Burkholderia cepacia infection who were hospitalized between June 2012 and September 2017. RESULTS: All 16 children with Burkholderia cepacia infection were sporadic cases. A total of 16 strains of Burkholderia cepacia were isolated, among which 8 were detected by sputum culture, 5 were detected by blood culture, 2 were detected by tracheal intubation tip culture, and 1 was detected by lung biopsy culture. Of the 16 children, there were 11 boys and 5 girls, with an age of 5 days to 6 years, and the children aged <1 year accounted for 69%. As for department distribution, 10 children were in the PICU/NICU and 6 were in the general wards. As for clinical manifestations, one child had disseminated intravascular coagulation, and the other 15 children had pulmonary infection, among who 11 had severe pneumonia (8 of them underwent mechanical ventilation during treatment). As for underlying diseases, 2 had severe congenital heart disease, 4 had primary immunodeficiency, 3 were highly suspected of immunodeficiency or inherited metabolic diseases, 1 had tracheal stenosis, 1 had Kawasaki disease, 1 was a preterm infant with bronchopulmonary dysplasia, 1 had severe cleft lip and palate, and 3 had no definite underlying diseases. Of all the children, 7 also had infections with adenovirus and Mycoplasma. The average length of hospital stay was 20.3 days for all children, and 12 were improved and 4 died after treatment. All 16 strains of Burkholderia cepacia had a drug resistance rate of 100% to amikacin and gentamicin and ≥80% to ampicillin/sulbactam and ticarcillin/clavulanic acid, as well as the lowest drug resistance rate to levofloxacin. CONCLUSIONS: Burkholderia cepacia is an opportunistic pathogen often found in immunocompromised children and can produce drug resistance. The presence or absence of underlying diseases should be considered during anti-infective therapy. The children with Burkholderia cepacia infection often have a poor prognosis, and an understanding of the disease spectrum of Burkholderia cepacia infection helps with clinical diagnosis and treatment.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[St] Status:In-Data-Review

  8 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29412110
[Au] Autor:Chaudhary R; Balhara M; Jangir D; Dangi M; Dangi M; Khatri S; Chhillar AK
[Ad] Address:Centre for Biotechnology, Maharshi Dayanand University, Rohtak-124001, Haryana. Indiana.
[Ti] Title:The Sesamum indicum rhizosphere associated bacterium: A source of Antifungal compound.
[So] Source:Curr Top Med Chem;, 2018 Feb 05.
[Is] ISSN:1873-4294
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:BACKGROUND: The impact of fungal infections on human health has increased considerably within a past few decades. Although drugs with antifungal properties are available, but they are less effective and are associated with side effects. OBJECTIVE AND METHOD: Screening of bacterial isolates from Sesamum indicum and to investigate the antifungal activity of the screened bacterial isolates against Aspergillus sp. Co-culture assay and agar overlay were used to scrutinize the anti-Aspergillus activity. Furthermore, optimization ofmedia and growth conditions to enhance the production of anti-Aspergillus compound. RESULTS: Several bacterial cultures were isolated from Sesamum indicum rhizosphere collected from Mandi (H.P.) India. These bacterial cultures were assayed for antifungal activity against Aspergillus species i.e. A. fumigatus and A. niger. Two most potent strains were chosen for more detailed analyses. The biochemical characterization and 16S ribosomal RNA sequencing revealed that Burkholderia sp. strain RC1 and Acinetobacter pittii strain RC2 exhibits strong similarity (100%) with Burkholderia sp. SR2-07 and Acinetobacter sp. strain 3-59. Additionally, it was also validated that RC1 and RC2 showed significant difference in the production of anti-Aspergillusactivity under altered growth conditions. CONCLUSION: Results from this study recommends that plant rhizosphere remains a rich hotspot for delivering a novel antifungal compounds.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180207
[Lr] Last revision date:180207
[St] Status:Publisher
[do] DOI:10.2174/1568026618666180206102140

  9 / 3730 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29405136
[Au] Autor:Singhal L; Kaur P; Gautam V
[Ad] Address:Department of Microbiology, Government Medical College and Hospital, Chandigarh, India.
[Ti] Title:: From trivial to grievous.
[So] Source:Indian J Med Microbiol;35(4):469-479, 2017 Oct-Dec.
[Is] ISSN:1998-3646
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Stenotrophomonas maltophilia, once regarded as an organism of low virulence, has evolved as a significant opportunistic pathogen causing severe human infections in both hospital and community settings, especially amongst highly debilitated patients. Globally, S. maltophilia ranks third amongst the four most common pathogenic non-fermenting Gram-negative bacilli (NFGNBs), others being Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia complex (Bcc). The worth of accurate identification of S. maltophilia comes to the forefront as it needs to be differentiated from other NFGNBs such as Acinetobacter, P. aeruginosa and Bcc due to its inherently contrasting antibiotic susceptibility pattern. Consequently, its correct identification is essential as no single drug is amply effective against all NFGNBs, which hinders initiation of appropriate empirical treatment resulting in increased morbidity and mortality.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180206
[Lr] Last revision date:180206
[St] Status:In-Data-Review
[do] DOI:10.4103/ijmm.IJMM_16_430

  10 / 3730 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29310479
[Au] Autor:El Chakhtoura NG; Saade E; Iovleva A; Yasmin M; Wilson B; Perez F; Bonomo RA
[Ad] Address:a Medicine , Case Western Reserve University School of Medicine , Cleveland , OH , USA.
[Ti] Title:Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.
[So] Source:Expert Rev Anti Infect Ther;16(2):89-110, 2018 Feb.
[Is] ISSN:1744-8336
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Non-fermenting Gram-negative bacilli are at the center of the antimicrobial resistance epidemic. Acinetobacter baumannii and Pseudomonas aeruginosa are both designated with a threat level to human health of 'serious' by the Centers for Disease Control and Prevention. Two other major non-fermenting Gram-negative bacilli, Stenotrophomonas maltophilia and Burkholderia cepacia complex, while not as prevalent, have devastating effects on vulnerable populations, such as those with cystic fibrosis, as well as immunosuppressed or hospitalized patients. Areas covered: In this review, we summarize the clinical impact, presentations, and mechanisms of resistance of these four major groups of non-fermenting Gram-negative bacilli. We also describe available and promising novel therapeutic options and strategies, particularly combination antibiotic strategies, with a focus on multidrug resistant variants. Expert commentary: We finally advocate for a therapeutic approach that incorporates in vitro antibiotic susceptibility testing with molecular and genotypic characterization of mechanisms of resistance, as well as pharmacokinetics and pharmacodynamics (PK/PD) parameters. The goal is to begin to formulate a precision medicine approach to antimicrobial therapy: a clinical-decision making model that integrates bacterial phenotype, genotype and patient's PK/PD to arrive at rationally-optimized combination antibiotic chemotherapy regimens tailored to individual clinical scenarios.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180129
[Lr] Last revision date:180129
[St] Status:In-Data-Review
[do] DOI:10.1080/14787210.2018.1425139


page 1 of 373 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information